GLSINasdaqPharmaceutical PreparationsFiscal year ends December 31
Greenwich LifeSciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$15.21+0.66 (+4.54%)
Close on Oct 19, 2026
- Market cap
- $222.39M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
11.5%
2M of 15M shares
Institutional holders
58
7 new, 11 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
13 buys · 0 sales
Net bought $586.33K
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GLSI | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 485,854 | 3.31% | $11.40M | +51,994 | 0.00% |
| Vanguard Capital Management LLC | 278,190 | 1.90% | $6.53M | −20,076 | 0.00% |
| Geode Capital Management, LLC | 168,179 | 1.15% | $3.95M | +12,713 | 0.00% |
| State Street Corp | 143,086 | 0.97% | $3.36M | +9,211 | 0.00% |
| Vanguard Portfolio Management LLC | 80,861 | 0.55% | $1.90M | +21,950 | 0.00% |
| Northern Trust Corp | 80,228 | 0.55% | $1.88M | +5,103 | 0.00% |
| Bank of New York Mellon Corp | 47,900 | 0.33% | $1.12M | +1,377 | 0.00% |
| Vanguard Fiduciary Trust Co | 45,965 | 0.31% | $1.08M | +1,057 | 0.00% |
| Morgan Stanley | 43,447 | 0.30% | $1.02M | +13,620 | 0.00% |
| Goldman Sachs Group Inc | 39,329 | 0.27% | $922.66K | −192 | 0.00% |
| Russell Investments Group, Ltd. | 34,353 | 0.23% | $805.94K | −5,344 | 0.00% |
| Jane Street Group, LLC | 27,694 | 0.19% | $649.70K | New | 0.00% |
| UBS Group AG | 23,409 | 0.16% | $549.18K | +2,293 | 0.00% |
| State Of Wisconsin Investment Board | 22,639 | 0.15% | $531.11K | +2,300 | 0.00% |
| Gsa Capital Partners Llp | 19,543 | 0.13% | $458 | New | 0.03% |
| Massachusetts Financial Services Co /Ma/ | 17,922 | 0.12% | $420.45K | New | 0.00% |
| Strs Ohio | 17,800 | 0.12% | $417.59K | +4,100 | 0.00% |
| Charles Schwab Investment Management Inc | 17,098 | 0.12% | $401.12K | +495 | 0.00% |
| Vanguard Global Advisers, LLC | 11,871 | 0.08% | $278.49K | +1,536 | 0.00% |
| Ancora Advisors, LLC | 10,740 | 0.07% | $251.96K | −26,760 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 58 | 2M | 11.5% | 7 / 24 | 15 / 11 | 0M | 0M |
| Q1 2026 | 64 | 2M | 11.7% | 24 / 18 | 12 / 9 | 1M | 0M |
| Q4 2025 | 50 | 1M | 9.0% | 7 / 15 | 18 / 8 | 0M | 0M |
| Q3 2025 | 51 | 1M | 8.3% | 5 / 16 | 14 / 5 | 0M | 0M |
| Q2 2025 | 51 | 1M | 8.4% | 9 / 20 | 11 / 3 | 0M | 0M |
| Q1 2025 | 46 | 1M | 7.9% | 7 / 10 | 13 / 2 | 0M | 0M |
| Q4 2024 | 42 | 1M | 8.0% | 6 / 16 | 6 / 3 | 0M | 0M |
| Q3 2024 | 39 | 1M | 7.8% | 9 / 12 | 8 / 3 | 0M | 0M |
| Q2 2024 | 34 | 1M | 7.0% | 13 / 11 | 5 / 10 | 1M | 0M |
| Q1 2024 | 31 | 1M | 4.5% | 7 / 10 | 5 / 3 | 0M | 0M |
| Q4 2023 | 27 | 1M | 3.7% | 6 / 11 | 4 / 3 | 0M | 0M |
| Q3 2023 | 24 | 1M | 3.7% | 2 / 4 | 9 / 1 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of GLSI | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 199,015 | 1.36% | $4.67M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 180,681 | 1.23% | $4.24M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 74,349 | 0.51% | $1.00M | 0.00% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 72,268 | 0.49% | $1.70M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 63,269 | 0.43% | $1.48M | 0.01% | Jun 30, 2026 |
| Vanguard U.S. Momentum Factor ETF | 34,273 | 0.23% | $897.10K | 0.05% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 33,114 | 0.23% | $866.76K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 32,771 | 0.22% | $857.78K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 22,686 | 0.15% | $532.21K | 0.03% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 16,211 | 0.11% | $218.85K | 0.00% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 12,325 | 0.08% | $322.61K | 0.00% | May 31, 2026 |
| Master Small Cap Index Series | 11,706 | 0.08% | $274.62K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 9,629 | 0.07% | $252.04K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 8,430 | 0.06% | $220.66K | 0.00% | May 31, 2026 |
| Nuveen Small Cap Blend Index Fund | 8,122 | 0.06% | $109.65K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Snehal Patel | CEO and CFO, Director, 10% owner | 8,324,288 | 56.71% | Jul 30, 2026 |
| Frank Joseph Daugherty | Chief Medical Officer, Director | 90,121 | 0.61% | Dec 27, 2024 |
| Jaye Thompson | VP Clinical Reg Affairs | 264,148 | 1.80% | Dec 27, 2024 |
| David McWilliams | Director | 620,301 | 4.23% | Dec 27, 2024 |
| Kenneth Hallock | Director | 794,308 | 5.41% | Dec 27, 2024 |
| Eric Rothe | Director | 313,226 | 2.13% | Dec 27, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Snehal Patel CEO and CFO, Director, 10% owner | Jul 29, 2026 | Buy | +700 | $13.10 | $9.17K | 5,611,402 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jul 28, 2026 | Buy | +1,500 | $13.59 | $20.39K | 5,610,702 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jul 27, 2026 | Buy | +1,500 | $13.62 | $20.43K | 5,609,202 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jul 24, 2026 | Buy | +1,100 | $12.88 | $14.17K | 5,607,702 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jul 23, 2026 | Buy | +2,500 | $13.14 | $32.85K | 5,606,602 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jan 13, 2026 | Buy | +1,800 | $29.83 | $53.69K | 5,604,102 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jan 12, 2026 | Buy | +2,900 | $27.54 | $79.87K | 5,602,302 |
| Snehal Patel CEO and CFO, Director, 10% owner | Dec 31, 2025 | Buy | +4,300 | $21.36 | $91.85K | 5,599,402 |
| Snehal Patel CEO and CFO, Director, 10% owner | Dec 30, 2025 | Buy | +2,900 | $21.73 | $63.02K | 5,595,102 |
| Snehal Patel CEO and CFO, Director, 10% owner | Dec 18, 2025 | Buy | +4,100 | $12.62 | $51.74K | 5,592,202 |
| Snehal Patel CEO and CFO, Director, 10% owner | Nov 25, 2025 | Buy | +4,600 | $8.37 | $38.50K | 5,588,102 |
| Snehal Patel CEO and CFO, Director, 10% owner | Nov 7, 2025 | Buy | +10,600 | $8.43 | $89.36K | 5,583,502 |
| Snehal Patel CEO and CFO, Director, 10% owner | Oct 31, 2025 | Buy | +2,300 | $9.26 | $21.30K | 5,572,902 |
| Snehal Patel CEO and CFO, Director, 10% owner | Apr 25, 2025 | Buy | +3,600 | $9.88 | $35.57K | 5,570,602 |
| Snehal Patel CEO and CFO, Director, 10% owner | Apr 17, 2025 | Buy | +5,400 | $8.98 | $48.49K | 5,567,002 |
| Snehal Patel CEO and CFO, Director, 10% owner | Apr 7, 2025 | Buy | +3,600 | $9.10 | $32.76K | 5,561,602 |
| Snehal Patel CEO and CFO, Director, 10% owner | Apr 4, 2025 | Buy | +5,500 | $8.73 | $48.02K | 5,558,002 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jan 10, 2025 | Buy | +2,500 | $12.51 | $31.28K | 5,552,502 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jan 7, 2025 | Buy | +1,800 | $13.75 | $24.75K | 5,550,002 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jan 6, 2025 | Buy | +1,100 | $13.31 | $14.64K | 5,548,202 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jan 3, 2025 | Buy | +3,400 | $12.95 | $44.03K | 5,547,102 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jan 2, 2025 | Buy | +2,000 | $11.97 | $23.94K | 5,543,702 |
| Snehal Patel CEO and CFO, Director, 10% owner | Dec 31, 2024 | Buy | +2,400 | $11.36 | $27.26K | 5,541,702 |
| Snehal Patel CEO and CFO, Director, 10% owner | Dec 30, 2024 | Buy | +3,200 | $11.12 | $35.58K | 5,539,302 |
| Jaye Thompson VP Clinical Reg Affairs | Nov 21, 2024 | Buy | +1,000 | $12.91 | $12.91K | 264,148 |
| Snehal Patel CEO and CFO, Director, 10% owner | Sep 26, 2024 | Buy | +1,500 | $14.63 | $21.95K | 5,536,102 |
| Jaye Thompson VP Clinical Reg Affairs | Aug 12, 2024 | Buy | +800 | $13.85 | $11.08K | 263,148 |
| Snehal Patel CEO and CFO, Director, 10% owner | Aug 6, 2024 | Buy | +2,000 | $13.81 | $27.62K | 5,534,602 |
| Snehal Patel CEO and CFO, Director, 10% owner | Aug 5, 2024 | Buy | +5,500 | $13.18 | $72.49K | 5,532,602 |
| Jaye Thompson VP Clinical Reg Affairs | Aug 2, 2024 | Buy | +1,000 | $15.15 | $15.15K | 262,348 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jul 23, 2024 | Buy | +1,500 | $15.89 | $23.84K | 5,527,102 |
| Jaye Thompson VP Clinical Reg Affairs | Jul 18, 2024 | Buy | +1,000 | $16.00 | $16.00K | 261,348 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jun 13, 2024 | Buy | +174,825 | $14.30 | $2.50M | 5,525,602 |
| Snehal Patel CEO and CFO, Director, 10% owner | Apr 1, 2024 | Buy | +3,000 | $19.08 | $57.24K | 5,350,777 |
| Snehal Patel CEO and CFO, Director, 10% owner | Mar 22, 2024 | Buy | +2,500 | $19.98 | $49.95K | 5,347,777 |
| Snehal Patel CEO and CFO, Director, 10% owner | Mar 20, 2024 | Buy | +1,500 | $17.68 | $26.52K | 5,345,277 |
| Snehal Patel CEO and CFO, Director, 10% owner | Mar 5, 2024 | Buy | +30,500 | $12.49 | $380.95K | 5,343,777 |
| Snehal Patel CEO and CFO, Director, 10% owner | Mar 5, 2024 | Buy | +3,500 | $12.49 | $43.72K | 5,343,777 |
| Snehal Patel CEO and CFO, Director, 10% owner | Mar 4, 2024 | Buy | +4,100 | $13.03 | $53.42K | 5,340,277 |
| Snehal Patel CEO and CFO, Director, 10% owner | Feb 16, 2024 | Buy | +10,800 | $11.16 | $120.53K | 5,336,177 |
| Snehal Patel CEO and CFO, Director, 10% owner | Feb 15, 2024 | Buy | +12,700 | $11.07 | $140.59K | 5,325,377 |
| Snehal Patel CEO and CFO, Director, 10% owner | Nov 10, 2023 | Buy | +5,000 | $10.17 | $50.85K | 5,312,677 |
| Snehal Patel CEO and CFO, Director, 10% owner | Nov 3, 2023 | Buy | +3,500 | $9.11 | $31.88K | 5,307,677 |
| Jaye Thompson VP Clinical Reg Affairs | Oct 27, 2023 | Buy | +500 | $8.57 | $4.29K | 260,348 |
| Snehal Patel CEO and CFO, Director, 10% owner | Oct 26, 2023 | Buy | +2,500 | $7.97 | $19.93K | 5,304,177 |
| Snehal Patel CEO and CFO, Director, 10% owner | Oct 25, 2023 | Buy | +2,500 | $7.91 | $19.78K | 5,301,677 |
| Snehal Patel CEO and CFO, Director, 10% owner | Oct 10, 2023 | Buy | +1,000 | $9.07 | $9.07K | 5,299,177 |
| Snehal Patel CEO and CFO, Director, 10% owner | Oct 4, 2023 | Buy | +2,000 | $8.63 | $17.26K | 5,298,177 |
| Jaye Thompson VP Clinical Reg Affairs | Sep 26, 2023 | Buy | +600 | $8.71 | $5.23K | 259,848 |
| Snehal Patel CEO and CFO, Director, 10% owner | Sep 19, 2023 | Buy | +4,000 | $8.95 | $35.80K | 5,296,177 |
| Snehal Patel CEO and CFO, Director, 10% owner | Sep 11, 2023 | Buy | +1,000 | $9.48 | $9.48K | 5,292,177 |
| Snehal Patel CEO and CFO, Director, 10% owner | Aug 22, 2023 | Buy | +1,000 | $9.97 | $9.97K | 5,291,177 |
| Snehal Patel CEO and CFO, Director, 10% owner | Aug 4, 2023 | Buy | +2,000 | $10.55 | $21.10K | 5,290,177 |
| Snehal Patel CEO and CFO, Director, 10% owner | Jul 21, 2023 | Buy | +1,000 | $9.20 | $9.20K | 5,288,177 |
| Jaye Thompson VP Clinical Reg Affairs | Jul 13, 2023 | Buy | +250 | $9.49 | $2.37K | 259,248 |
| Snehal Patel CEO and CFO, Director, 10% owner | May 17, 2023 | Buy | +1,000 | $11.69 | $11.69K | 5,287,177 |
| Jaye Thompson VP Clinical Reg Affairs | Apr 28, 2023 | Buy | +250 | $11.22 | $2.81K | 258,998 |
| Snehal Patel CEO and CFO, Director, 10% owner | Apr 19, 2023 | Buy | +7,000 | $11.10 | $77.70K | 5,286,177 |
| Snehal Patel CEO and CFO, Director, 10% owner | Apr 18, 2023 | Buy | +2,000 | $11.12 | $22.24K | 5,279,177 |
| Jaye Thompson VP Clinical Reg Affairs | Apr 11, 2023 | Buy | +1,000 | $11.87 | $11.87K | 258,745 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.